In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this second episode, Joel sits down with Shivani Srivastava, PhD, Assistant Professor Human Biology Division, Fred Hutchinson Cancer Research Center, to explore:

• Key challenges to addressing solid tumors with cell therapy
• Recent developments (technology, scientific understanding) that are lowering these barriers
• The ultimate promise offered by cell therapy for solid tumor patients (what a 'win' looks like)
• Thoughts about what can and will be achieved, and over what timeframe

©2023 Lumanity Inc.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this first episode, Joel sits down with Michael Parisi, CEO of Guidemark, and Michael Rice, Vice President, Head of Advanced Therapeutics, to explore:

• How uncovering NSCLC and SMA genetics led to record-speed options for patients with rare subtypes
• How the patient advocacy groups enabled translation
• How the provider infrastructure is evolving to meet the need for genetic precision
• What pharma brought upon entering and how the lessons shape their and field's outlook
• What's next for rare disease drug development

©2023 Lumanity Inc.